Business Wire

Chiesi Accelerates Path Toward Full Sustainability Despite Covid-19 Pandemic

Share

Chiesi, the international research-focused pharmaceutical and healthcare Group (Chiesi Group), further accelerated its path toward becoming a fully sustainable company, despite an extremely challenging 2020, which was overshadowed by the Covid-19 pandemic. This is the thread running through Chiesi’s Annual & Sustainability Report 2020.

The Group in 2020 turned in a robust financial performance, with revenues amounting to €2,229 million, up by 11.8% compared to 2019. It provides Chiesi with impetus to continue its transformational journey to become the world’s first fully sustainable pharmaceutical company, in which value generation for the planet and for society enables the creation of innovation, progress and prosperity.

Transparent impact measurement methodology that integrates ESG (environmental, social, and corporate governance) topics and impact frameworks

As in previous years, Chiesi is reporting how it operates in accordance with a comprehensive combination of multiple tools and frameworks. This includes the methodology pioneered by renowned economist Professor Jeffrey Sachs of the Columbia Center on Sustainable Development, which assesses Chiesi’s business impact through an analysis of products, processes, global value chain and corporate citizenship, in full alignment with the United Nations 2030 Agenda of Sustainable Development Goals (SDGs). Chiesi’s Annual & Sustainability Report further meets the standards of the Global Reporting Initiative, a non-profit organisation set up to support companies when reporting on sustainable performance, the B Impact Assessment™ created by B Lab, the non-profit organisation behind the B Corp certification, and the SDG Action Manager from UN Global Compact and B Lab.

Patients’ medical treatment top priority during pandemic

In a year unlike any other in the Group’s history, Chiesi worked relentlessly to protect patients and ensure their unhindered access to life-saving medical treatments despite the disruptions to supplies and public healthcare services caused by the pandemic. The company established a dedicated team to coordinate the collection and deployment of financial and in-kind donations to support communities during the Covid-19 emergency. In addition, Chiesi maintained the production of medical products, especially those which were essential or needed to treat rare diseases. Overall, the company directly donated or raised more than €10.6 million, of which over €3.5 million contributed to charitable projects in the Parma area and Italy nationwide.

“The pandemic has changed the world with full force in what were already transformative times. Within this context of adversity and the need to manage the unknown, I am grateful for the organisation that we have demonstrated to be. The mobilisation of Chiesi’s people has gone beyond the scope of our business and attested the values we share together. Our shared value approach, as a certified B Corp and a Benefit Corporation, demonstrates that the values we stand for represent the solid foundation our company needs for the challenges of our time,” said Ugo Di Francesco, CEO of Chiesi Group.

From product focus to full patient-centricity

In 2020 Chiesi dedicated more than 20% of its revenues to R&D, which placed Chiesi as the top Italian pharmaceutical company for number of patents filed. A commitment was also put in place to accelerate the transformation of its business and corporate culture towards adopting a holistic and patient-centric perspective at every stage of the product development cycle. The streamlining of the Group’s brand architecture – with the three areas Air, Rare and Care inspired by the non-medical language patients use, and the re-launch of the Chiesi visual identity in early 2021 are direct outcomes of the Group’s ongoing evolution of embedding empathy with the patient experience into all business processes.

Several new strategic collaborations with external partners that Chiesi entered into in 2020 will help to further bolster this patient-oriented approach. This includes the partnerships with Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics, to develop new therapies against pulmonary arterial hypertension. Another example of the Chiesi patient-centric innovation approach is its investment in Cyclica. The Canadian neo biotech company is working on decentralising the discovery of drugs through an innovative supervised learning AI technology for predicting molecular properties in the R&D phase to reduce attrition rates and the time from bench to patient.

Continued focus on Diversity & Equality in the workplace

Despite the challenges for workplace organisation as a result of the pandemic, Chiesi further increased the number of employees to 6,389 in 2020, a growth of around 9% on the previous year. Around 53% of the Group’s workforce, and more than a quarter of executives and senior managers, are women. The ratio of female employees is even higher in the Research & Development area (64%).

Chiesi’s leadership in diversity and equality in the workplace was once again demonstrated by the Financial Times’s annual Diversity Leaders ranking, in which the company was ranked 10th worldwide. The ranking assesses 850 European employers on the diversity of gender, age, ethnicity, disability and sexual orientation in their workforces. Chiesi is one of only two Italian companies in the top 10 and ranked 1st within the pharmaceutical and biotechnology industry.

Chiesi remains committed to enhancing diversity and equality in the workplace. Following the creation of the Diversity and Inclusion Committee in 2019, the company established a Gender Equality Committee in 2020. In 2021, Chiesi is developing and implementing an action plan for improved female talent development practices to close the gender gap.

Chiesi raises the level of ambition towards carbon neutrality

Following the first announcement in 2019, in May 2021, Chiesi unveiled its plan to become carbon neutral by 2030 with regard to direct greenhouse gas (GHG) emissions and indirect GHG emissions from purchased electricity and heat (scopes 1 and 2) and by 2035 on all the other indirect GHG emissions (scope 3) on www.actionoverwords.org. This will include a 90% reduction of emissions from Chiesi’s inhaler devices compared to 2019, thanks to the planned introduction of an innovative low global warming potential propellant.

Chiesi’s green energy transition on a global scale

In 2020, all of Chiesi’s Italian sites, representing around 80% of its total energy consumption, were powered by 100% renewable energy. The Group signed a new contract for its 2021 and 2022 energy supply from the wind farm MELFI II, a new wind farm located in a high wind area in Puglia region (Italy). 100% of the electricity used at the Parma sites comes from high-quality renewable sources; 2.6% is generated from Chiesi’s own plants (self-production) with a total capacity of 780 kW (+670 kW compared to the previous year). In 2021, Chiesi intends to complete the transition to 100% renewable electricity at all manufacturing sites.

Total energy consumption in 2020 decreased by 15% compared to 2019. This was mainly driven by a reduction in energy use from the car fleet due to the Covid-19 pandemic. The Group’s new Headquarters in Parma (Italy), inaugurated in 2020, is also a totally green building and is LEED Platinum certified, the highest level of the international building sustainability rating system promoted by the Green Building Council.

About Chiesi Group

Based in Parma, Italy, Chiesi is an international research-focused pharmaceuticals and healthcare group with over 85 years’ experience, operating in 30 countries with more than 6,000 employees (Chiesi Group). To achieve its mission of improving people’s quality of life by acting responsibly towards society and the environment, the Group research, develops and markets innovative drugs in its three therapeutic areas: AIR (products and services that promote respiration, from new-born to adult populations), RARE (treatment for patients with rare and ultra-rare diseases) and CARE (products and services that support special care and consumer-facing self-care). The Group’s Research and Development centre is based in Parma and works alongside 6 other important research and development centres in France, the U.S., Canada, China, the UK, and Sweden to promote its pre-clinical, clinical, and regulatory programmes. Chiesi, since 2019, is the world’s largest B Corp certified pharmaceutical group. Chiesi Farmaceutici S.p.A. has changed in 2018 its legal status to a Benefit Corporation, by incorporating a double purpose for the creation of shared value, and to generate value for its business, for society and the environment. The global B Corp movement promotes business as a force for good. Moreover, as a Benefit Corporation, Chiesi Farmaceutici S.p.A. is required by law to include objectives of common benefit in its bylaws and to report annually in a transparent way. The Group is committed to becoming carbon neutral by the end of 2035.

For further information: www.chiesi.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Alessio Pappagallo
Press Office Manager
Phone +39 339 589 483
Email a.pappagallo@chiesi.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Adagio Therapeutics Partners with Biocon Biologics to Bring Potent and Broadly Neutralizing COVID-19 Antibody Treatment to Patients in India and Select Emerging Markets26.7.2021 22:05:00 CEST | Press release

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced a partnership agreement with Biocon Biologics Ltd., to combat the ongoing COVID-19 crisis in southern Asia. Biocon Biologics Ltd. is a fully integrated biosimilars company and a subsidiary of Biocon Ltd., a global biopharmaceuticals company, (BSE code: 532523, NSE: BIOCON). Under the terms of the agreement, Adagio will provide Biocon with materials and know-how to manufacture and commercialize an antibody treatment based on ADG20 in India and additional select emerging markets. ADG20, Adagio’s lead product candidate, is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 as either a single or combination agent. Unlike other antibody-based therapies specifically targeting SARS-CoV-2, ADG20 has demons

SpeeDx Launch Solution for SARS-CoV-2 Variant Analysis26.7.2021 18:40:00 CEST | Press release

SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have launched a new product line of research reagents to support reflex variant analysis for circulating SARS-CoV-2 variants of concern (VOC). The rapid development of PlexPrime® SARS-CoV-2 Genotyping* tests will support investigations and monitoring of the range of emerging and circulating SARS-CoV-2 VOC that have been linked to increased transmissibility, reduced vaccine efficacy, or other characteristics that may require specific public health actions.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210726005313/en/ SpeeDx unique technology excels in mutation detection applications and can readily be applied to variants reported in the SARS-CoV-2 sequence databases. Compatible with standard qPCR instrumentation, the PlexPrime® SARS-CoV-2 Genotyping research reagents can reduce the manual process of preparing positive samples for sequence analysis

V-Square Appoints Erik Norland as Head of Distribution26.7.2021 17:00:00 CEST | Press release

V-Square Quantitative Management (V-Square) has announced the hiring of Erik Norland as its Head of Distribution. A 20-year industry veteran with asset management, custody, and global markets expertise, Erik’s addition to the team bolsters our strong client-centric approach to deliver customized ESG solutions as we continue to build our reputation as a specialized global asset manager. He will lead the firm's sales, consultant relationship and client service functions across institutional, insurance and wholesale. Mr. Norland, based in Stockholm, will report to Mamadou-Abou Sarr, co-founder and President and will join the global leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210726005571/en/ Erik Norland, Head of Distribution (Photo: Business Wire) "Erik is a results-focused leader who brings excellent experience in distribution strategy and execution, sales management and client relationship roles. I had th

Private and Public Sector Join Forces Under the Umbrella of the kENUP Foundation: BioNTech Announces Project to Develop the First mRNA-Based Prophylactic Malaria vaccine, and the set-up of Manufacturing Infrastructures in Africa26.7.2021 16:10:00 CEST | Press release

Today, BioNTech SE (“BioNTech”) announced the start of its Malaria project which aims at the development of a safe and highly effective malaria vaccine and the implementation of sustainable vaccine supply solutions on the African continent. The company’s project is part of a programme by the kENUP Foundation to accelerating the eradication of Malaria. This goal was out of reach so far, despite enormous financial and public health efforts of the global community. The scientific and entrepreneurial progress made during the COVID-19 pandemic raise hopes that a highly efficacious vaccine could soon help to eradicate Malaria. BioNTech aims to develop a safe and highly effective mRNA vaccine with durable protective immunity for prevention of malaria and disease associated mortality. To this end, BioNTech will assess multiple vaccine candidates featuring known Malaria targets such as the circumsporozoite protein (CSP), as well as new antigens discovered in the pre-clinical research phase. The

PPG to Expand Production Capacity for PPG ISENSE Gloss Beverage Can Coatings at Delaware, Ohio, Plant26.7.2021 15:02:00 CEST | Press release

PPG (NYSE:PPG) today announced that it is currently adding capacity for the production of overvarnish coatings for beverage can exteriors, including PPG ISENSE™ Gloss coatings, at its Delaware, Ohio, plant. PPG expects the addition of the Delaware plant’s new volume to existing overvarnish capacity at its Oak Creek, Wisconsin, packaging coatings facility will increase the company’s overall production of overvarnish coatings in the U.S. by 40%. “Beverage can manufacturers around the world are facing unprecedented demand for their products,” said Todd White, PPG general manager, U.S. and Canada, and global strategic accounts, packaging coatings. “With this added capacity, we are committed to helping them meet that demand while adding more security to their supply chain for beverage can coatings.” In addition to increasing supply chain security for its customers and the packaging industry, the Delaware plant will provide in-line analytical capabilities for enhanced batch consistency. “PPG

NET ZERO Leaders Summit (Japan Business Conference 2021) - Online Event From Wednesday, July 28 : Latest Information26.7.2021 15:00:00 CEST | Press release

Japan’s Ministry of Economy, Trade and Industry (METI) and the Japan External Trade Organization (JETRO) are pleased to announce the jointly organized “NET ZERO Leaders Summit (Japan Business Conference 2021)” to accelerate innovation in green investment and the realization of carbon neutrality. The event will take place from Wednesday, July 28, and will be held online. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210726005389/en/ Entrance_Lobby_Image (Graphic: Business Wire) Main Program In the main program, panel discussions will be held between 15 leaders of global companies and organizations. In addition, Mr. SASAKI Nobuhiko, Chairman and CEO of the Japan External Trade Organization (JETRO), will present the opening remarks, Mr. TOKURA Masakazu, Chairman of KEIDANREN (Japan Business Federation), will present the keynote speech and Prime Minister SUGA Yoshihide and Minister of Economy, Trade and Industry KAJIYAMA Hirosh

ADM Accelerates Growth of Leading Global Alternative Protein Platform with Planned Acquisition of Sojaprotein26.7.2021 14:05:00 CEST | Press release

Global nutrition leader ADM (NYSE: ADM) announced today that it has reached an agreement to acquire Sojaprotein, a leading European provider of non-GMO soy ingredients. Established in 1977, Serbia-based Sojaprotein has sales into 65 countries, offering a wide array of non-GMO vegetable protein ingredients for an extensive list of European and global customers in the meat alternative, confectionary, protein bar, pharmaceutical, pet food, and animal feed segments. The company had more than $100 million in sales in 2020. “Thirty years ago, ADM invented the soy vegetable burger, giving rise to the plant-based protein segment. Today, alternative proteins represents one of our core growth platforms, and as this $10 billion global industry grows to $30 billion over the next decade, we are investing to expand our unparalleled capabilities,” said Leticia Gonçalves, ADM’s president of Global Foods. “The addition of Sojaprotein – the largest producer of plant-based protein in southern Europe – ad